DoH, ADIO And GSK Join Forces To Establish Multi-omics Research Institute In Abu Dhabi

The Department of Health – Abu Dhabi (DoH) and the Abu Dhabi Investment Office (ADIO) have partnered with GSK to establish a Multi-omics Research Institute in Abu Dhabi. This collaboration, announced during Abu Dhabi Global Health Week (ADGHW), aims to advance genomic science and precision medicine in oncology. The initiative seeks to diversify and enhance global genomic research, ultimately improving outcomes for cancer patients.

Multi-omics research involves studying various biological molecules like genes, RNA, proteins, and metabolites. This approach helps scientists understand their interactions within organisms. By integrating data from these areas, researchers can gain comprehensive insights into biological processes, enhancing understanding of health and disease.

The MoU was signed by prominent figures including Mansoor Al Mansoori, Chairman of DoH; Ahmed Jasim Al Zaabi, Chairman of ADDED; Sir Jonathan Symonds, Chairman of GSK; Boyd Chongphaisal, Vice President and General Manager of Gulf Countries at GSK; Dr. Noura Al Ghaithi, Under-Secretary of DoH; Badr Al-Olama, Director-General of ADIO; and Hesham A. Abdullah, Senior Vice President at GSK.

Dr. Noura Khamis Al Ghaithi stated that the initiative aligns with their vision to develop an advanced healthcare system globally. She emphasised the importance of using cutting-edge technologies and scientific research to drive precision medicine and personalised therapies worldwide. The institute will produce high-quality omics data to support innovative healthcare solutions.

Badr Al-Olama highlighted that establishing the multi-omics institute is a crucial step in positioning Abu Dhabi as a global hub for health innovation. By integrating early-stage discovery science into the local ecosystem, it supports vital oncology research while reinforcing the emirate's leadership in biotechnology and precision medicine.

Dr. Hesham Abdullah remarked that this MoU is pivotal in leveraging scientific excellence in the Middle East to generate multi-omic data. Such collaborations are essential for advancing translational research capabilities and accelerating oncology drug discovery.

Global Health Week Initiatives

ADGHW is a significant government initiative by DoH focusing on innovation under the theme ‘Towards Longevity: Redefining Health and Well-being.’ It emphasises community-driven health with preventive, personalised care approaches. Discussions will revolve around four themes: Longevity and Precision Health; Health System Resilience & Sustainability; Digital Health & AI; and Investment in Life Sciences.

This multinational effort will utilise Abu Dhabi’s advanced biotechnology infrastructure to embed early-stage discovery research within the UAE for the first time. It aims to foster scientific innovation in oncology while enhancing diversity in genomic research for cancer patient benefits.

The collaboration underscores Abu Dhabi’s commitment to international partnerships that drive preventative initiatives and oncology drug discovery. By bringing together diverse stakeholders globally, ADGHW aims to advance future health and well-being without borders.

With inputs from WAM